Compare ENVX & AGIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ENVX | AGIO |
|---|---|---|
| Founded | 2006 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.6B |
| IPO Year | 2020 | 2013 |
| Metric | ENVX | AGIO |
|---|---|---|
| Price | $4.93 | $27.80 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 9 | 8 |
| Target Price | $13.61 | ★ $37.63 |
| AVG Volume (30 Days) | ★ 5.3M | 708.3K |
| Earning Date | 05-21-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 40.94 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $31,821,000.00 | ★ $43,011,000.00 |
| Revenue This Year | $40.85 | $75.68 |
| Revenue Next Year | $236.84 | $167.63 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 37.91 | N/A |
| 52 Week Low | $4.67 | $22.24 |
| 52 Week High | $16.49 | $46.00 |
| Indicator | ENVX | AGIO |
|---|---|---|
| Relative Strength Index (RSI) | 34.41 | 46.37 |
| Support Level | N/A | $26.48 |
| Resistance Level | $8.73 | $29.49 |
| Average True Range (ATR) | 0.37 | 1.13 |
| MACD | 0.01 | -0.17 |
| Stochastic Oscillator | 13.92 | 25.09 |
Enovix Corp is engaged in designing, developing, manufacturing, and commercializing Lithium-ion, or Li-ion, battery cells. It uses BreakFlow and Encapsulation technologies to manufacture high capacity and resilient batteries. The company's product portfolio comprises power disc batteries, flexible lithium-ion polymer batteries, superior lithium-ion polymer batteries, active silicon lithium-ion cells, and others. Geographically, the company generates maximum revenue from its customers in South Korea, followed by Switzerland, the United States, Norway, Taiwan, and other regions.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.